# A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy

> **NCT06945107** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 308 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Picankibart
- **DRUG:** Secukinumab
- **DRUG:** Placebo
- **DRUG:** Ixekizumab

## Key facts

- **NCT ID:** NCT06945107
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2026-06-07
- **Final completion:** 2027-01-19
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06945107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06945107, "A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT06945107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*